SKY-LABS
22.2.2021 15:02:11 CET | Business Wire | Press release
Sky Labs , a healthcare start-up, announced that CART-I, its ring-type heart-monitoring device, had been provided for Timothy Betts, professor of medicine at Oxford University, for his clinical research.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210222005010/en/
Professor Timothy Betts is a cardiologist and arrhythmia specialist. He is a key figure for clinical research in cardiac rhythm management and associate professor of cardiovascular medicine at Oxford University. He is also a member of the Oxford Biomedical Research Center and the UK representative on the EHRA National Cardiac Societies Committee.
Atrial fibrillation patients are advised to take anticoagulants to prevent the risk of stroke. However, it is not easy to identify the symptoms. Professor Betts plans to conduct a clinical study with Sky Labs CART-I, Medtronic Reveal LINQ II and Apple Watch to detect atrial fibrillation symptoms and alert the patients to take anticoagulants when needed.
Fifty patients recruited for the study will be inserted with a Reveal LINQ II implantable cardiac monitor (ICM). Then they will receive a Sky Labs CART-I ring or an Apple Watch. The ability of the ring and the watch to monitor heart rhythm and alert atrial fibrillation episodes will be analyzed in comparison with the ICM.
CART-I is the world’s first ring-type heart-monitoring device. The photoplethysmography (PPG) sensor in the ring monitors the bloodstream in the finger and continuously measures the irregular pulse waves of atrial fibrillation. Electrocardiogram (ECG) can be also measured by simply placing the fingers on the metal part of the ring.
Professor Timothy Betts said, “I’m pleased to conduct a study to monitor the atrial fibrillation of patients by using CART-I and utilize the data to guide atrial fibrillation treatment. CART-I featuring innovative design and multiple functions will be of great help to patients and medical staffs.”
Jack Lee, CEO of Sky Labs, said, “The study will be an opportunity for us to enter the global healthcare market. CART-I will make a good combination with the ICM in monitoring heart rhythm and providing meaningful data for patients and doctors.”
Sky Labs’ CART-I won the Digital Health & Technology Competition of the European Society of Cardiology for 2 consecutive years from 2018. The company was selected as the ‘technology pioneer’ of the World Economic Forum 2019 and invited to the annual forum.
About Sky Labs
Sky Labs developed CART (Cardio Tracker) – I, a ring-type medical device to monitor heart signals and detect diseases by using optical sensors. It monitors atrial fibrillation, which cannot be detected in advance, 24/7. The results can be checked in real time on the CART-app of your smartphone. Very light and water-resistant, the CART ring is easy to use and causes no inconvenience to your daily life. Winning the final of the Grants4Apps held by Bayer, a German multinational pharmaceutical company, in 2017, Sky Labs attracted investment from Bayer Headquarters. Sky Labs and the Charité in Germany, one of Europe’s largest hospitals, have been considering collaborative clinical research in heart-related diseases since May 2018. It is the only Korean company which won the Digital Health and Technology Competition of the European Society of Cardiology for 2 consecutive years. In addition, the company was invited as a technology pioneer to the World Economic Forum 2019.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005010/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aarhus Vand Selects Netmore for Smart Meter Network25.8.2026 08:00:00 CEST | Press release
Partnership between Netmore, Aarhus Vand, and Kamstrup supports digitalization of metering network and water conservation across Aarhus Municipality, Denmark Netmore Group, the leading network operator and platform provider for Massive IoT, today announced a collaboration with Aarhus Vand and Kamstrup to support the deployment of approximately 69,000 digitally connected water meters across Aarhus Municipality, Denmark. Powered by Netmore's carrier-grade LoRaWAN® network and Kamstrup's digital water metering technology, the project will provide Aarhus Vand with real-time visibility into water consumption while helping residents better understand and reduce their water usage. Rollout begins in Tranbjerg following a successful pilot involving approximately 1,000 households, where the communication between Kamstrup's digital meters and Aarhus Vand was validated. The full deployment will continue through 2030, covering communities across Aarhus Municipality. The new water meters will elimin
Motorola Solutions fuldfører opkøbet af D-Fend Solutions25.8.2026 08:00:00 CEST | Pressemeddelelse
Beskyttelse af luftrummet for beredskabsmyndigheder og kritisk infrastruktur med differentieret, ikke-kinetisk RF-teknologi til cyberovertagelse Motorola Solutions (NYSE: MSI) har gennemført opkøbet af D-Fend Solutions (D-Fend), der er en førende virksomhed inden for anti-drone-teknologi, for en købspris på 1,5 mia. USD. Handlen giver beredskaber og erhvervsliv adgang til avancerede systemer til bekæmpelse af ubemandede luftfartøjer (C-UAS), der er udviklet til sikkert at neutralisere trusler fra uautoriserede droner. "Sikkerhed på jorden kræver sikkerhed i luften," siger Greg Brown, der er bestyrelsesformand og CEO i Motorola Solutions. "D-Fends gennemprøvede anti-drone-teknologi er et stærkt supplement til vores beredskabsløsninger og giver vores kunder verden over en differentieret beskyttelse af luftrummet." Præcis trusselsbegrænsning I modsætning til traditionelle anti-drone-metoder, der baserer sig på simpel detektion efterfulgt af jamming eller nedskydning, identificerer D-Fends
IFF Report Finds GLP-1 Is Reshaping Food Choices and Eating Behaviors Among Indian Consumers25.8.2026 07:30:00 CEST | Press release
Research highlights emerging opportunities for food and beverage innovation IFF (NYSE: IFF) — a global leader in flavors, fragrances and health and biosciences — released new research examining how GLP-1 use is influencing food behaviors among Indian consumers and what those shifts may mean for the future of food and beverage innovation. The study is the latest in IFF’s GLP-1 global consumer insights following the company’s 2025 GLP-1 Consumer Opportunity Outlook. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824816059/en/ “We are seeing that a change in appetite can lead to a broader change in the relationship people have with food, from how much consumers eat to how they choose, experience and participate in eating occasions,” said Harsch Koshti, regional marketing director, IFF Taste for Greater Asia. “For the food industry, this is a critical opportunity to listen closely to these emerging behaviors and think about h
Tigo Energy and Ingeteam Sign Certificate of Compatibility25.8.2026 06:00:00 CEST | Press release
Successful testing between Tigo MLPE and Ingeteam inverters validates an open ecosystem with proven compatibility for European solar installers. Tigo Energy, Inc. (NASDAQ: TYGO), a leading provider of intelligent solar and energy solutions, today announced a Certificate of Compatibility with European energy technology leader, Ingeteam S.A., documenting which Ingeteam inverters and Tigo Flex MLPE products have passed compatibility testing. The certificate covers certain single-phase and three-phase INGECON® SUN products and members of the Tigo TS4 MLPE product family, when properly designed and installed. Together, these products are designed to deliver high-quality, enhanced value with a system that can generate and manage solar energy more efficiently and provide the features that solar energy customers in the residential, Commercial and Industrial (C&I) and Utility segments demand. Ingeteam, a leading decarbonization and energy transformation company building a sustainable future thr
Celltrion Expands Omlyclo® Portfolio in Europe with Launch of 300 mg Strength25.8.2026 00:40:00 CEST | Press release
Omlyclo® (omalizumab) 300 mg launched in key European markets including Germany, the UK and France, with rollout to expand across Europe by year-endOmlyclo® 300 mg strength available in both pre-filled syringe (PFS) and autoinjector (AI) presentationsMultiple dose strengths and device options broaden treatment flexibility for healthcare professionals Celltrion (KRX: 068270) today announced the launch of the 300 mg strength of Omlyclo® (omalizumab), a treatment for chronic spontaneous urticaria and allergic asthma, in Europe.1 With the addition of the 300 mg strength, Celltrion has expanded its Omlyclo® portfolio to include multiple dose strengths and device presentations for patients, healthcare professionals and healthcare institutions. Following the European launch of Omlyclo® 75 mg and 150 mg late last year, Celltrion began rolling out the 300 mg strength in key markets including Germany, the UK and France in the middle of this year. Celltrion is gradually expanding supply to other
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
